NOVARTIS

Olema Oncology collaborates with Novartis for Phase III trial of palazestrant and Kisqali in ER+/HER2-negative metastatic breast cancer, funded by $250m private placement. Palazestrant, a CERAN and SERD, aims to improve outcomes in resistant cancers, with potential revenue of $855m by 2030.

Novartis pays $1 billion upfront to license PTC518, a Huntington's disease drug, with potential for $1.9 billion in milestone payments and royalties. PTC retains 40% of U.S. profits and leads Phase 2 completion and FDA discussions. The deal is expected to close in Q1 2025.

PTC receives $1bn from Novartis for Phase II Huntington’s candidate, with potential additional $1.9bn for milestones and US profit sharing. Discussions on accelerated approval with the US FDA are ongoing.

FDA approves Phase II trial for Ruxoprubart, a selective alternative pathway inhibitor, in IgAN patients, with potential to treat multiple disorders. Ruxoprubart's unique mechanism avoids blocking the classical pathway, offering advantages over existing treatments.

Subscribe to BioWorld™ news services.

The article discusses the importance of enabling JavaScript for optimal app performance.

Novartis partners with PTC Therapeutics for up-to-$2.9 billion to develop PTC518 for Huntington's disease, with $1 billion upfront and potential $1.9 billion in milestones and royalties. PTC518 showed dose-dependent reductions in mutant Huntingtin protein levels and potential for accelerated FDA approval.

Novartis to pay up to $3 billion for PTC Therapeutics' experimental Huntington's disease drug, PTC518, in a deal that includes $1 billion upfront and potential milestone payments of $1.9 billion. The agreement reflects Novartis' commitment to neurodegenerative disease research and PTC's focus on RNA splicing therapies.